My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 193

    1.

    Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL.

    Ann Intern Med. 1997 Nov 15;127(10):855-65.PMID: 9382363 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.

    Wong JB, Bennett WG, Koff RS, Pauker SG.

    JAMA. 1998 Dec 23-30;280(24):2088-93.PMID: 9875876 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis.

    Davis GL, Beck JR, Farrell G, Poynard T.

    J Viral Hepat. 1998 Sep;5(5):313-21.PMID: 9795915 [PubMed - indexed for MEDLINE]Related articles

    4.

    Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

    Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group.

    Gut. 2003 Mar;52(3):425-32.PMID: 12584228 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

    Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.PMID: 15461877 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.

    JAMA. 2003 Jul 9;290(2):228-37.PMID: 12851278 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

    Wong JB, Koff RS, Tinè F, Pauker SG.

    Ann Intern Med. 1995 May 1;122(9):664-75.PMID: 7702228 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

    Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators.

    Health Technol Assess. 2006 Jul;10(21):1-113, iii.PMID: 16750059 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

    Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.

    Pharmacoeconomics. 2004;22(4):257-65.PMID: 14974875 [PubMed - indexed for MEDLINE]Related articles

    10.

    Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

    Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

    Am J Gastroenterol. 2004 Aug;99(8):1490-6.PMID: 15307866 [PubMed - indexed for MEDLINE]Related articles

    11.

    Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.

    Sennfält K, Reichard O, Hultkrantz R, Wong JB, Jonsson D.

    Scand J Gastroenterol. 2001 Aug;36(8):870-6.PMID: 11495084 [PubMed - indexed for MEDLINE]Related articles

    12.

    Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

    Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, Bassendine M, Main J, Thomas H.

    Gut. 2006 Sep;55(9):1332-8. Epub 2005 Jun 30.PMID: 15994216 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

    Shepherd J, Jones J, Takeda A, Davidson P, Price A.

    Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.PMID: 16904047 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

    Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG.

    Am J Gastroenterol. 2000 Jun;95(6):1524-30.PMID: 10894590 [PubMed - indexed for MEDLINE]Related articles

    15.

    Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

    Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB.

    Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006.PMID: 19485429 [PubMed - indexed for MEDLINE]Related articles

    16.

    Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness.

    Wong JB.

    Acta Gastroenterol Belg. 1998 Apr-Jun;61(2):238-42.PMID: 9658620 [PubMed - indexed for MEDLINE]Related articles

    17.

    Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

    Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

    Health Technol Assess. 2007 Mar;11(11):1-205, iii. Review.PMID: 17346498 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

    Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R.

    Aliment Pharmacol Ther. 2003 Mar 1;17(5):687-94.PMID: 12641518 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.

    Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB Jr.

    Ann Intern Med. 1997 Nov 15;127(10):866-74.PMID: 9382364 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.

    Wong JB, Davis GL, Pauker SG.

    Am J Med. 2000 Apr 1;108(5):366-73.PMID: 10759092 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity